Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the two doses actually compare — and what changes when you move from one to the other
What is Mounjaro 2.5mg actually for?
A question our prescribers hear most weeks is whether 2.5mg is a "low dose" in the sense of being less effective. It isn't quite that straightforward. The 2.5mg pen exists specifically as a tolerability step: tirzepatide activates both GIP and GLP-1 receptors simultaneously, and introducing that dual action gradually gives your digestive system time to settle. Nausea, constipation and other gastrointestinal effects are most pronounced when starting or increasing, so the first four weeks at 2.5mg are largely about adjustment rather than weight loss.
That said, some people do begin to notice appetite changes at 2.5mg. The medicine is working biologically from day one; the dose is simply calibrated to reduce early discomfort rather than maximise effect. You can read more about how the full dose ladder fits together on the different doses of Mounjaro page.
Clinical trials supporting Mounjaro's licence tested the medicine across its full dosing programme; the meaningful weight-loss outcomes reported in SURMOUNT-1, published in the New England Journal of Medicine, were measured at 10mg and 15mg maintenance doses. The 2.5mg period precedes that, not replaces it.
What changes at 5mg — and how significant is the step?
Moving from 2.5mg to 5mg is when treatment shifts from adjustment to active therapy. At 5mg the appetite-suppressing and metabolic effects of tirzepatide become more pronounced for most people. Gastric emptying slows more noticeably, hunger signals ease, and the calorie reduction that drives weight loss tends to become more consistent day to day.
Side effects can resurface briefly at 5mg, just as they did at 2.5mg, because the body is again adapting to a higher level of the medicine. This usually settles within the first week or two. The timing and spacing of your weekly injection matters during this period; the recommended interval between doses should stay as consistent as possible to keep blood levels stable.
5mg is not a final destination for most people on Mounjaro. The licensed schedule continues through 7.5mg, 10mg, 12.5mg and 15mg, each introduced by your prescriber when the previous dose is well tolerated. Jumping steps early, or staying at 5mg indefinitely without clinical review, is not recommended. How dose titration works in practice is worth understanding before starting treatment.
Is there a meaningful weight-loss difference between 2.5mg and 5mg?
Yes. The difference in weight-loss outcomes between 2.5mg and 5mg is real, though it should be seen in context. In clinical trial data, weight loss at higher doses was substantially greater than at lower ones. The SURMOUNT-1 programme, as NICE notes in its appraisal of tirzepatide (TA1026), showed average body-weight reductions of around 15% at 10mg and around 20–21% at 15mg over 72 weeks. Comparable long-term data at 2.5mg or 5mg as a maintained dose were not the focus of the trials, because those doses are designed as steps, not endpoints.
In practical terms: expecting the same effect at 2.5mg as at 10mg would be unrealistic. The titration schedule is built to get people to the highest dose they tolerate well, and that is where the headline trial results apply. See the 5mg Mounjaro page for more detail on what to expect at that specific dose.
| Feature | 2.5mg | 5mg |
|---|---|---|
| Primary purpose | Tolerability and adjustment | First active therapeutic dose |
| Typical duration at this dose | 4 weeks (starter period) | 4 weeks, then reviewed by prescriber |
| Appetite suppression | Mild to moderate in most people | More noticeable for most people |
| Side-effect likelihood | Highest at initiation; often settles quickly | Can briefly resurface; usually transient |
| Expected as a maintenance dose | No | No, further titration is the norm |
| Long-term weight-loss evidence | Not the primary trial endpoint [NEJM, SURMOUNT-1] | Not the primary trial endpoint [NICE TA1026] |
Can you stay at 2.5mg or 5mg long-term, or request a slower titration?
Both are clinical questions with real answers. Some people do spend longer at 2.5mg or 5mg, not by choice, but because their prescriber judges that moving up too quickly would cause unnecessary side effects. That is a legitimate, guided decision, not a treatment failure. Titration pace should reflect how the individual is tolerating the medicine, not a calendar.
Requesting to hold at a given dose temporarily is something many people raise with their prescriber. Staying at 5mg indefinitely is different: the cost of ongoing treatment is one practical consideration, but the more important one is clinical, whether staying at 5mg is achieving a meaningful and sustained outcome, or whether moving up would be appropriate.
The interval between doses is also fixed: once weekly, on the same day where possible. If you want to understand how flexibility works in practice, the guidance on how many days can fall between Mounjaro doses clarifies the licensed window. Which dose is right for you, and for how long, is a decision our prescribers make with you, not something any page can determine on your behalf. Check your eligibility and start a free consultation to have that conversation with a clinician.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.